other material
confidence high
sentiment positive
materiality 0.85
Positive topline results from VIRAGE Phase 2b trial: VCN-01+SoC improves OS, PFS, DoR in metastatic pancreatic cancer
Theriva Biologics, Inc.
- Median OS 10.8 vs 8.6 months for VCN-01+SoC vs SoC alone (HR=0.57, p=0.0546).
- Median PFS 7.0 vs 4.6 months (HR=0.55, p=0.0105).
- Median DoR doubled to 11.2 vs 5.4 months (HR=0.22, p=0.0035).
- 2-dose VCN-01 + ≥4 cycles SoC subgroup: median OS 14.8 vs 11.6 months (HR=0.44, p=0.046).
- Safety met primary endpoint; AEs transient/reversible, consistent with prior trials.